Synergy Pharmaceuticals, Inc.
420 Lexington Avenue
Suite 1609
New York,
NY 10170
United States - Carte
Téléphone: 212-297-0020
Télécopie: 212-297-0019
Site Web: http://www.synergypharma.com
| Abonnement à l'indice: | N/D | | Secteur: | Healthcare | | Secteur: | Drug Manufacturers - Other | | Employés à plein temps: | 18 |
|
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate includes plecanatide, a guanylyl cyclase C receptor agonist that has completed Phase IIa clinical trials to treat chronic idiopathic constipation GI disorders, as well as is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company also develops SP-333, which is in Phase I clinical trials to treat GI inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. Statistiques clés
| |
| | Paye | Exercé | Dr. Gary S. Jacob Ph.D.,
66
Chief Exec. Officer, Pres and Director | 562,00K | 0,00 | Mr. Bernard F. Denoyer CPA, M.B.A.,
65
Principal Financial Officer, Principal Accounting Officer, Sr. VP of Fin. and Sec. | 246,00K | 0,00 | Dr. Kunwar Shailubhai Ph.D.,
55
Chief Scientific Officer | 317,00K | 0,00 | Dr. Laura Barrow Pharm. D.,
Sr. VP of Clinical Operations | N/D | N/D | Dr. Stephen Comiskey Ph.D.,
VP of Product Devel. | N/D | N/D |
|
| | Les montants sont en date du 2012-12-30 et les valeurs de rémunération correspondent au dernier exercice financier se terminant à cette date. Paye correspond à salaire, bonus, etc. Exercé est la valeur des options exercées pendant lannée fiscale. | | Devise en USD. |
|
0.74%